EMA/330057/2014

# European Medicines Agency decision

P/0149/2014

of 13 June 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno-associated viral vector serotype 9 containing human sulfamidase gene (EMEA-001502-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

# European Medicines Agency decision

P/0149/2014

of 13 June 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno-associated viral vector serotype 9 containing human sulfamidase gene (EMEA-001502-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Laboratorios Dr. Esteve S.A on 8 July 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 April 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

***Article 1***

A paediatric investigation plan for adeno-associated viral vector serotype 9 containing human sulfamidase gene, solution for injection/infusion, intracerebroventricular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

***Article 2***

A deferral for adeno-associated viral vector serotype 9 containing human sulfamidase gene, solution for injection/infusion, intracerebroventricular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

***Article 3***

A waiver for adeno-associated viral vector serotype 9 containing human sulfamidase gene, solution for injection/infusion, intracerebroventricular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

***Article 4***

This decision is addressed to Laboratorios Dr.Esteve S.A, Av. Mare de Déu de Montserrat, 221, 08041 - Barcelona, Spain.

Done at London, 13 June 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/57027/2014

# Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001502-PIP01-13

## Scope of the application

**Active substance(s):**

Adeno-associated viral vector serotype 9 containing human sulfamidase gene

**Condition(s):**

Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)

**Pharmaceutical form(s):**

Solution for injection/infusion

**Route(s) of administration:**

Intracerebroventricular use

**Name/corporate name of the PIP applicant:**

Laboratorios Dr. Esteve S.A

## Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Laboratorios Dr. Esteve S.A submitted for agreement to the European Medicines Agency on 8 July 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 August 2013.

Supplementary information was provided by the applicant on 22 January 2014.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 25 April 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

# 1. Waiver

## *1.1. Condition: treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)*

The waiver applies to:

- the paediatric population from birth to less than 28 days;
- for solution for injection/infusion, intracerebroventricular use;
- on the grounds that the specific medicinal product is likely to be unsafe.

# 2. Paediatric Investigation Plan

## *2.1. Condition: treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)*

### 2.1.1. Indication(s) targeted by the PIP

Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age.

### 2.1.3. Pharmaceutical form(s)

Solution for injection/infusion

### 2.1.4. Measures

| Area | Number of studies | Description |
|---|---|---|
| Quality-related studies | | Not applicable. |
| Non-clinical studies | 4 | Study 1) Non-clinical safety study: Dose Range finding (DRF) tolerance study in mice<br>Study 2) Dose Range finding (DRF) tolerance study in dogs<br>Study 3) 6-month toxicology in mice<br>Study 4) 6-month toxicology dogs |
| Clinical studies | 4 | Study 5) 1369910153609<br>Open-label study to evaluate the safety, tolerability and activity of two different doses of Adeno-associated viral vector serotype 9 human Sulfamidase after intracerebroventricular administration to mucopolysaccharidosis type IIIA patients |

| Area | Number of studies | Description |
|---|---|---|
| | | Study 6) 1369977873968<br>Multicentre, observational study to evaluate disease progression in untreated patients with MPS IIIA.<br>Study 7) 1369979526031<br>Multicentre, open-label, natural history controlled study to confirm the efficacy and safety/tolerability of intracerebroventricular administration of Adeno-associated viral vector serotype 9 containing human sulfamidase gene (AAV9–hSulfamidase)<br>Study 8) 1369982527312<br>Open-label study to evaluate the activity and safety/tolerability of intracerebroventricular administration of Adeno-associated viral vector serotype 9 containing human sulfamidase gene (AAV9–hSulfamidase) |

## 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Concerns on potential long term safety issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By December 2022 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |